Timetable

Clinical Trials Development work group and experimental-translational work group:

The coherence and effectiveness of the work plan will be underpinned by our use of COST Tools.

1. Clinical Trials development WG:

a. Objectives:
i. To prioritize the cancer type and design protocols for prospective randomised controlled trials evaluating perioperative interventions on cancer recurrence or metastasis.
ii. To submit agreed protocols of prospective trials for large scale funding,
iii. To implement, across our own centres and others the delivery of definitive trials that will provide Level 1 evidence based medical data this vital clinical question.
iv. To train young early stage investigators in the skills and expertise needed to engage in this research by offering them training attachments in partner units that may have that expertise.

b. Tasks
i. To meet in person in a formal COST Action Workshop twice yearly initially to discuss the delivery of the objectives;
ii. To apportion and expedite the work involved in progressive stages
iii. To organise formal COST Action Training for members of the Work Group as necessary in order for them to effectively undertake their agreed tasks. It is envisaged that this training would take place within the group where
possible. This may be particularly beneficial for our Young Investigators.
iv. Centre Visits are another COST Tool that may be combined with the Workshop Tool and the Training Tool to maximise cost efficacy, and will facilitate member learning and relevant up skilling.

c. Milestones:
i. That these proposer meetings take place and complete a full discussion of all ideas raised, with an action plan agreed to deliver progress;
ii. Development of protocol for a prospective, randomised controlled trial.  

d. Deliverable:
i. Submission of prospective clinical trial;

ii. Obtaining funding to undertake this trial 
iii. Publication of interim and / or definitive data in high impact peer reviewed journals as it emerges.


2. Experimental-translational WG:

a. Objectives
i. To meet in person in a formal COST Action Workshop twice yearly initially to discuss the delivery of the objectives;
ii. To identify Short Term Scientific Missions to continue to develop collaborative translational and experimental studies evaluating mechanisms underpinning potential effect of perioperative interventions during cancer surgery on postoperative recurrence or metastasis.
iii. To organise formal COST Action Training for members of the Work Group as necessary in order for them to effectively undertake their agreed tasks. For example, this might include funding the attendance of COST Action
members at Master Classes in Applying for Research Funding, or equivalent.
iv. COST Action Visits are another Tool that will enable proposers to streamline Good Clinical Practice in their own institutions by observing and learning from the practice in other like-minded institutions with more experience in
clinical research.
v. Dissemination of knowledge from completed studies in peer reviewed manuscripts and also in selected cases, to mainstream media, where the significance of any new finding may warrant such publicity.

b. Tasks
i. To meet and discuss all relevant proposed ideas for new projects and agree an action plan to implement them according to the WG’s priorities;
ii. To construct quality experimental and translational studies on the mechanisms by which for example, anaesthetic and analgesic drugs might influence cancer cell biology, or how perioperative innate immune function may be modulated to facilitate cancer resistance.

c. Milestones
i. Commencement of such studies involving at least two or more of our constituent centres in collaboration;

d. Deliverables
i. Publication of these studies in anaesthesia or oncological journal literature.
ii. Informing the design of clinical trials in the other Work Group based on the most likely mechanism of action of various interventions on cancer cell biology.